Antigen Presentation, Apoptosis/Cell Death, Autoimmunity, Cell Biology, Cellular Differentiation, Cellular Immunity, Dendritic Cells, Gene Discovery, Immunological Tolerance, Immunology, Infectious Disease, Knockout Mice, Lymphocytes, Lysosomes/endosome, Macrophage, Microarray, Signal Transduction, T Cells, Tolerance, Transgenic Mice, Vaccine Development
BS, American University of Beirut
, University of California
PhD, University of Pittsburgh School of Medicine
, Yale University School of Medicine
Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease
MSSM Faculty Council 'Junior Faculty Award for Academic Excellence'
Hirschl Scholar Award
Irma T. Hirschl/Monique Weill-Caulier
Harold and Golden Lamport Award
J.V. Satterfield Award
Specific Clinical/Research Interest: Innate immunity, apoptosis, inflammation and the control of adaptive immunity.
Current Students: Priyanka Nair, PhD student and Andrew Kent, MD/PhD graduate student.
Postdoctoral Fellows: Gaetan Barbet, Ph.D., Laura Campisi, Ph.D., Diego Mourao-Sa, Ph.D., Soumit Roy, Ph.D., Julien Moretti, Ph.D, Nicolas Vabret, Ph.D.
Research Coordinator: Cheri Korb.
Julie Magarian Blander, PhD, is the Director of the Innate Immunity Research Program. The laboratory focuses on elucidating the innate immune mechanisms controlling inflammation, host defense and adaptive immunity.
1. Garaude, J, Kent, A, van Rooijen, N, and Blander, JM, Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Science translational medicine, 2012. 4(120): p. 120ra116. [Abstract] [Reprint] [Full text]
2. Puga, I, Cols, M, Barra, CM, He, B, Cassis, L, Gentile, M, Comerma, L, Chorny, A, Shan, M, Xu, W, Magri, G, Knowles, DM, Tam, W, Chiu, A, Bussel, JB, Serrano, S, Lorente, JA, Bellosillo, B, Lloreta, J, Juanpere, N, Alameda, F, Baro, T, de Heredia, CD, Toran, N, Catala, A, Torrebadell, M, Fortuny, C, Cusi, V, Carreras, C, Diaz, GA, Blander, JM, Farber, CM, Silvestri, G, Cunningham-Rundles, C, Calvillo, M, Dufour, C, Notarangelo, LD, Lougaris, V, Plebani, A, Casanova, JL, Ganal, SC, Diefenbach, A, Arostegui, JI, Juan, M, Yague, J, Mahlaoui, N, Donadieu, J, Chen, K, and Cerutti, A, B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nature immunology, 2012. 13(2): p. 170-180. [Abstract]
3. Nair, P, Amsen, D, and Blander, JM, Co-ordination of incoming and outgoing traffic in antigen-presenting cells by pattern recognition receptors and T cells. Traffic, 2011. 12(12): p. 1669-1676. [Abstract]
4. Sander, LE, Davis, MJ, Boekschoten, MV, Amsen, D, Dascher, CC, Ryffel, B, Swanson, JA, Muller, M, and Blander, JM, Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature, 2011. 474(7351): p. 385-389. [Abstract]
5. Brereton, CF and Blander, JM, The unexpected link between infection-induced apoptosis and a TH17 immune response. Journal of leukocyte biology, 2011. 89(4): p. 565-576. [Abstract]
6. Garaude, J and Blander, JM, ICOStomizing immunotherapies with T(H)17. Science translational medicine, 2010. 2(55): p. 55ps52. [Abstract]
7. Brereton, CF and Blander, JM, Responding to infection and apoptosis--a task for TH17 cells. Annals of the New York Academy of Sciences, 2010. 1209: p. 56-67. [Abstract]
8. Torchinsky, MB, Garaude, J, and Blander, JM, Infection and apoptosis as a combined inflammatory trigger. Current opinion in immunology, 2010. 22(1): p. 55-62. [Abstract]
9. Torchinsky, MB and Blander, JM, T helper 17 cells: discovery, function, and physiological trigger. Cellular and molecular life sciences : CMLS, 2010. 67(9): p. 1407-1421. [Abstract]
10. Sander, LE and Blander, JM, Innate immune cells cast an eye on DNA. Journal of molecular cell biology, 2009. 1(2): p. 77-79. [Abstract]
11. Blander, JM and Amsen, D, Immunology. Amino acid addiction. Science, 2009. 324(5932): p. 1282-1283. [Abstract]
12. Sander, LE and Blander, JM, Inflammasome and toll-like receptor 9: Partners in crime in toxic liver injury. Hepatology, 2009. 49(6): p. 2119-2121. [Abstract]
13. Blander, JM, Analysis of the TLR/NF-kappaB pathway in antigen-presenting cells in malignancies promoted by inflammation. Methods Mol Biol, 2009. 512: p. 99-117. [Abstract]
14. Torchinsky, MB, Garaude, J, Martin, AP, and Blander, JM, Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature, 2009. 458(7234): p. 78-82. [Abstract]
15. Blander, JM, Phagocytosis and antigen presentation: a partnership initiated by Toll-like receptors. Annals of the rheumatic diseases, 2008. 67 Suppl 3: p. iii44-49. [Abstract]
16. Blander, JM, Signalling and phagocytosis in the orchestration of host defence. Cellular microbiology, 2007. 9(2): p. 290-299. [Abstract]
17. Blander, JM, Coupling Toll-like receptor signaling with phagocytosis: potentiation of antigen presentation. Trends in immunology, 2007. 28(1): p. 19-25. [Abstract]
18. Blander, JM and Medzhitov, R, On regulation of phagosome maturation and antigen presentation. Nature immunology, 2006. 7(10): p. 1029-1035. [Abstract]
19. Blander, JM and Medzhitov, R, Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature, 2006. 440(7085): p. 808-812. [Abstract]
20. Blander, JM and Medzhitov, R, Regulation of phagosome maturation by signals from toll-like receptors. Science, 2004. 304(5673): p. 1014-1018. [Abstract]
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Blander did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.